TY - JOUR
T1 - Pharmacotherapy for Small Fiber Neuropathy
AU - George, Tikku
AU - Kafaie, Jafar
AU - Huang, Zi Ling
AU - Profirovic, Jasmina
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - Purpose of review: Small fiber neuropathy (SFN) is a condition that affects small nerve fibers leading to a variety of symptoms, including pain, discomfort, tingling, and sensory loss. The development of new drugs is commonly complicated by variable medication pharmacokinetics and patients’ response to treatment due to comorbidities. In this review, we discuss currently used drugs, including the evidence about their efficacy. We also mention the medications with a questionable response in SFN treatment and those that are potential emerging therapies. Recent findings: SFN treatment is aimed towards addressing the cause of neuropathy and alleviating its symptoms. Determining the best treatment option may be challenging. Current drug treatments include antiseizure drugs, antidepressants, opioids, immunomodulating agents, topical medications, and NMDA antagonists. Each of these drugs has different molecular targets, efficacy, and adverse effect profiles. In some cases, the exact underlying mechanisms are not well understood. Summary: Current drug treatments provide patients with varying, often suboptimal, relief of symptoms. The need for new, effective, and safe therapies for SFN warrants intensive development and testing of new agents.
AB - Purpose of review: Small fiber neuropathy (SFN) is a condition that affects small nerve fibers leading to a variety of symptoms, including pain, discomfort, tingling, and sensory loss. The development of new drugs is commonly complicated by variable medication pharmacokinetics and patients’ response to treatment due to comorbidities. In this review, we discuss currently used drugs, including the evidence about their efficacy. We also mention the medications with a questionable response in SFN treatment and those that are potential emerging therapies. Recent findings: SFN treatment is aimed towards addressing the cause of neuropathy and alleviating its symptoms. Determining the best treatment option may be challenging. Current drug treatments include antiseizure drugs, antidepressants, opioids, immunomodulating agents, topical medications, and NMDA antagonists. Each of these drugs has different molecular targets, efficacy, and adverse effect profiles. In some cases, the exact underlying mechanisms are not well understood. Summary: Current drug treatments provide patients with varying, often suboptimal, relief of symptoms. The need for new, effective, and safe therapies for SFN warrants intensive development and testing of new agents.
KW - Neuropathic pain
KW - Neuropathy management
KW - Pain treatment
KW - Small fiber neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85095615714&partnerID=8YFLogxK
U2 - 10.1007/s11940-020-00652-2
DO - 10.1007/s11940-020-00652-2
M3 - Review article
AN - SCOPUS:85095615714
SN - 1092-8480
VL - 22
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 12
M1 - 41
ER -